Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2010
06/23/2010CN101744975A Method for detecting compound lightyellow sophora root injection
06/23/2010CN101744948A Extract from fruit shell of camellia oleifera abel and preparation method and application thereof
06/23/2010CN101744886A Method for extracting high-purity schisandra total lignan
06/23/2010CN101744877A Selfheal quality control method
06/23/2010CN101744874A Compound bee emulsion for resisting tumor and preparation method thereof
06/23/2010CN101744864A Method for preparing health-care product of peanut skin biological agent
06/23/2010CN101744856A Application of jerusalem artichoke extract in preparing anti-tumor medicine or anti-tumor health care product
06/23/2010CN101744854A Xiaoaiping pill and preparing method thereof
06/23/2010CN101744853A Antineoplastic drug taking panaxadiol saponins as active ingredient and application thereof
06/23/2010CN101744849A Glabrous sarcandra herb dripping pill and preparation technology
06/23/2010CN101744848A Application of FHL3 (four and a half LIM domains 3) in preparation of medicines for treating tumors
06/23/2010CN101744847A Agaricus compound polysaccharide capsule preparation method
06/23/2010CN101744846A Edible mycotic composite amylase nutritional agent
06/23/2010CN101744841A Collins john kevin; o'sullivan gerald christopher; o'mahony liam; shanahan fergus
06/23/2010CN101744837A Preparation method for sinonovacula constricta enzymolysis liquid with diversified bioactivities
06/23/2010CN101744832A Chinese traditional medicine preparation for reversing multiple medicine resistance of tumor cells and preparation method thereof
06/23/2010CN101744819A Sinomenine and luteolin composition and anti-angiogenic drug taking sinomenine and luteolin composition as active ingredient having synergistic action
06/23/2010CN101744818A Sinomenine and honokiol composition and anti-angiogenic drug taking sinomenine and honokiol composition as active ingredient having synergistic action
06/23/2010CN101744807A Epigallocatechin-3-gallate pharmaceutical composition and freeze-dried powder injection thereof
06/23/2010CN101744803A Method for preparing oridonin solid dispersion
06/23/2010CN101744802A Novel application of hydroxysafflor yellow A to preparation of anti-tumour drugs
06/23/2010CN101744800A Nedaplatin medical composition and application
06/23/2010CN101744770A Ginseng polysaccharide injection and preparation method thereof
06/23/2010CN101744767A Thermal sensitive liposome preparation containing camptothecin antineoplastic agents
06/23/2010CN101744766A Preparing technique of nano magnetic gene-loaded liposome of temperature-controlled release
06/23/2010CN101744764A Blank and topotecan hydrochloride containing polycystin liposome and preparation method thereof
06/23/2010CN101744650A System for transferring anti-hepatitis b virus vaccine
06/23/2010CN101744360A Antrodia camphorata extract and cigarette containing antrodia camphorata extract
06/23/2010CN101744285A Method for preparing emulsified and gelatinized functional fatty acid carrier
06/23/2010CN101255158B 9-N-substituted berberine derivatives as well as preparation method and use as anti-cancer drugs
06/23/2010CN101181571B Traditional Chinese medicine for curing cancer
06/23/2010CN101167962B Orally-administered traditional Chinese medicinal formula for treating leukemia
06/23/2010CN101161645B Urea derivatives as well as preparation method and uses thereof
06/23/2010CN101099781B External-applied traditional Chinese medicine for treating middle and late brain tumor
06/23/2010CN101077384B Application of traditional Chinese medicine preparation in preparing medicine for treating and preventing gynaecologic disease
06/23/2010CN101073643B Chinese-medicinal preparation for preventing and treating hypogalactias and and gynecopathy, its production and use
06/23/2010CN101011091B Fermented tea, extract of fermented tea, composition for inhibiting elevation of blood sugar value, and beverage and foodstuff
06/23/2010CN101007815B Pyrrolehexa-heterocyclic compound and pharmaceutical use thereof
06/23/2010CA2653163A1 Methods for the treatment of acute myeloid leukemia
06/23/2010CA2647655A1 Novel c-1 analogs of pancratistan and 7-deoxypancratistatin and processes for their preparation
06/22/2010USRE41393 such as [1S-[1R*,3R*(E), 7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,13,17-trioxabicyclo[14.1.0]heptadecane-5,9-dione, used treat cancers that have demonstrated resistance to other oncolytic agents
06/22/2010US7741468 protein hLRTM4 and the polynucleotide which encodes it; used to treat liver injury, hepatocellular carcinoma
06/22/2010US7741465 Chimeric receptor genes and cells transformed therewith
06/22/2010US7741452 produced by introducing amino acid mutation(s) so that no glycosylation take place at at least one glycosylation site of hepatocyte growth factor; more stable in the blood circulation
06/22/2010US7741447 Antibody against tumor specific antigen as target
06/22/2010US7741445 Multidrug resistance proteins; xenobiotic transporters; counteracting the mechanism of drug resistance so to provide a longer and more effective course of chemotherapeutic drug treatment for cancer patients
06/22/2010US7741444 Neoplasm specific antibodies and uses thereof
06/22/2010US7741440 Apoptin-associating protein
06/22/2010US7741439 Isolated stra6 polypeptides
06/22/2010US7741346 Vision defects; anticancer agents; antitumor agents
06/22/2010US7741338 mixtures comprising a polyene macrolide antibiotic and an antioxidant such as 2,6-di-tert.-butyl-4-methylphenol, that improves the stability of the polyene macrolide to oxidation
06/22/2010US7741336 N-(1-Methyl-1-phenyl-ethyl)-3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-5-trifluoromethyl-pyrimidin-4-ylamino]-methyl}-benzenesulfonamide, useful in the treatment of breast cancer
06/22/2010US7741330 1-((S)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-2,3-dihydroxypropan-1-one, used for the treatment of autoimmune diseases, inflammatory diseases, allergy disorders, B-cell proliferative disorders, or thromboembolic disorders
06/22/2010US7741329 such as 1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-2-yl-methanone, used as human orexin receptor antagonist, for the treatment of obesity and insomnia
06/22/2010US7741328 Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds
06/22/2010US7741325 Benzo[b]chromeno-naphthyridin-7-one and pyrano[2′,3′:7,8]quino[2,3-b]quinoxalin-7-one compounds
06/22/2010US7741319 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
06/22/2010US7741312 Benzylaminosulfonic Acid or portion or analogue linked to a carbohydrate or glycomimetic for modulating processes mediated by selectin binding such as autoimmune and inflammatory diseases, shock and reperfusion injuries
06/22/2010US7741297 Cpg sites; point mutations; immunogens; cancer
06/22/2010US7741295 Detecting activity of a Silent information regulator 2 by combining the composition with adenosine 5'-diphosphate and an acetylated Sir2 peptide substrate to deacetylate the peptide, and identifying 2'/3'-O-acetyl-ADP-ribose in the mixture to determine the presence of Sir2 activity
06/22/2010US7741282 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein
06/22/2010US7741280 Multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments
06/22/2010US7741278 Modified proteins, designer toxins, and methods of making thereof
06/22/2010US7741276 Use of interleukin-18 inhibitors to inhibit tumor metastasis
06/22/2010US7741272 Inhibiting angiogenesis in a mammal by administering Eph receptor antagonist ; cardiovascular disorders
06/22/2010US7741115 for modulating or altering T cell function; found on lymphoid derived dendritic cells and display a limited homology to adhesion molecules; generating natural killer cells
06/22/2010US7741078 Heparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same
06/22/2010US7741057 Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor
06/22/2010US7740853 Fcepsilon-pe chimeric protein for targeted treatment of allergy responses a method for its production and pharmaceutical compositions containing the same
06/22/2010US7740841 Therapeutic method for reducing angiogenesis
06/22/2010US7740834 Murine zcytor17 ligand polypeptides
06/22/2010US7740830 Imaging, diagnosis and treatment of disease
06/22/2010CA2579915C Indole derivatives and their use as inhibitors of p53-mdm2 interaction
06/22/2010CA2514977C Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)
06/22/2010CA2480409C Novel pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
06/22/2010CA2479991C Process for production of crystals, crystals obtained thereby and their use in pharmaceutical preparations
06/22/2010CA2469225C Citric acid salt of 4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one and pharmaceutical compositions thereof
06/22/2010CA2462149C Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
06/22/2010CA2461187C Lyophilized formulation
06/22/2010CA2447300C Cell-specific replication-competent vector
06/22/2010CA2439062C Silicon implants comprising a radionuclide for use in brachytherapy
06/22/2010CA2420996C Substituted heterocyclic compounds for treating multidrug resistance
06/22/2010CA2406177C 8.beta.-hydrocarbyl-substituted estratrienes as selectively active estrogens
06/22/2010CA2395493C Hyaluronic acid in the treatment of cancer
06/22/2010CA2384059C Method of treating cancer using tetraethyl thiuram disulfide
06/22/2010CA2353905C Chemotherapeutic composition and method
06/22/2010CA2302568C Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
06/22/2010CA2297198C Macrocyclic lactones, compositions, and methods of use
06/22/2010CA2295577C Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumors originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma
06/22/2010CA2256483C P13 lipid kinase
06/22/2010CA2216963C Tie-2 ligands, methods of making and uses thereof
06/17/2010WO2010068947A2 Nuclear export inhibitors of topoisomerase ii alpha
06/17/2010WO2010068923A2 Agents that selectively inhibit cd25 on dendritic cells or t cells and their use
06/17/2010WO2010068920A2 Diaminoquinazoline inhibitors of dihydrofolate reductase
06/17/2010WO2010068877A2 Compounds that bind oxysterol binding proteins, and methods of use thereof
06/17/2010WO2010068816A1 Gnaq targeted dsrna compositions and methods for inhibiting expression
06/17/2010WO2010068815A2 Compositions and methods for treating cellular proliferative disorders
06/17/2010WO2010068810A2 Certain substituted amides, method of making, and method of use thereof
06/17/2010WO2010068806A1 Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
06/17/2010WO2010068794A2 Hif inhibitors and use thereof
1 ... 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 ... 2211